Tamura H, Ishii S, Ikeda T, Wada N, Enomoto K, Kitajima M
Department of Surgery, Keio University, School of Medicine, Japan.
Surg Oncol. 1996 Jun;5(3):141-7. doi: 10.1016/s0960-7404(96)80014-4.
Bone metastasis is clinically often recognized in breast cancer patients, and in the progression of bone destruction due to bone metastasis, osteoclastic bone resorption is an important step. Therefore, drugs such as bisphosphonates-which have anti-osteoclastic activity-are expected to inhibit the progression of bone metastasis. However, bisphosphonates demonstrate no cytotoxic effects for cancer cells. In the present study we have evaluated the therapeutic efficacy of pamidronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid) combined with mitomycin C (MMC) on bone metastasis of breast cancer using an animal model. The model for bone metastasis was developed by injecting c-SST-2 (spontaneously developed rat mammary adenocarcinoma in a SHR rat) cells into the thoracic aorta of 45-46 day-old female SHR rats. Three weeks after the tumour cell injection, these 48 animals were divided into four groups: control, n = 16; pamidronate, n = 12; MMC, n = 10; pamidronate with MMC, n = 10). In order to evaluate therapeutic effects on bone metastasis in each animal, the whole spine was harvested for histological examination. The bone metabolic markers used were: pyridinoline/creatinine (Pyd/Cr), deoxypyridinoline/creatinine (Dpd/Cr), bone alkaline phosphatase (BAP), and osteocalcin-measured 1 week after therapy. Histological scores of bone destruction in the treatment groups were lower than those of the control, and there were no differences among treatment groups. Although the values of Pyd/Cr and Dpd/Cr in the treatment groups, including pamidronate, were significantly lower than those in the control (P < 0.05), the other markers did not differ. It was suggested that pamidronate inhibited the progression of bone resorption, mainly by osteoclast activation due to bone metastasis, and Pyd/Cr and Dpd/Cr could be useful in part as a marker which reflects therapeutic effect. However, no additional effects were observed when it was combined with MMC.
骨转移在临床上常出现在乳腺癌患者中,在因骨转移导致的骨质破坏进展过程中,破骨细胞性骨吸收是重要一步。因此,具有抗破骨细胞活性的双膦酸盐类药物有望抑制骨转移的进展。然而,双膦酸盐对癌细胞无细胞毒性作用。在本研究中,我们使用动物模型评估了帕米膦酸(3-氨基-1-羟丙基亚丙基-1,1-双膦酸)联合丝裂霉素C(MMC)对乳腺癌骨转移的治疗效果。通过将c-SST-2(SHR大鼠自发产生的大鼠乳腺腺癌)细胞注入45-46日龄雌性SHR大鼠的胸主动脉来建立骨转移模型。肿瘤细胞注射三周后,将这48只动物分为四组:对照组,n = 16;帕米膦酸组,n = 12;MMC组,n = 10;帕米膦酸联合MMC组,n = 10)。为了评估对每只动物骨转移的治疗效果,采集整个脊柱进行组织学检查。使用的骨代谢标志物为:吡啶啉/肌酐(Pyd/Cr)、脱氧吡啶啉/肌酐(Dpd/Cr)、骨碱性磷酸酶(BAP)和骨钙素——在治疗1周后测量。治疗组骨破坏的组织学评分低于对照组,各治疗组之间无差异。虽然包括帕米膦酸在内的治疗组中Pyd/Cr和Dpd/Cr的值显著低于对照组(P < 0.05),但其他标志物无差异。提示帕米膦酸主要通过抑制因骨转移导致的破骨细胞活化来抑制骨吸收的进展,Pyd/Cr和Dpd/Cr可部分作为反映治疗效果的标志物。然而,与MMC联合使用时未观察到额外效果。